SYNTHETIC PEPTIDES DERIVED FROM E7 REGION OF HUMAN PAPILLOMAVIRUS TYPE-16 USED AS ANTIGENS IN ELISA

被引:44
作者
KRCHNAK, V
VAGNER, J
SUCHANKOVA, A
KRCMAR, M
RITTEROVA, L
VONKA, V
机构
[1] INST SERA & VACCINES, CS-10103 PRAGUE 10, CZECHOSLOVAKIA
[2] POSTGRAD MED & PHARMACEUT INST, CS-10005 PRAGUE 10, CZECHOSLOVAKIA
关键词
D O I
10.1099/0022-1317-71-11-2719
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Nine overlapping peptides (20 amino acid) covering the entire sequence of early antigen E7 of human papillomavirus type 16 (HPV-16) were synthesized and tested as antigens with human sera in ELISA. Five of these peptides (no. 1 to 5 counting from the N terminus of the E7 protein) reacted with a pool of sera from HPV-16-infected individuals (as determined by molecular hybridization with their biopsy specimens); one (no. 5) was also reactive with pools of HPV-18- and HPV-6- or 11-infected individuals. Sera from 24 patients with cervical intraepithelial neoplasia (CIN) and from 29 invasive cervical carcinoma (INCA) patients were tested for the presence of antibodies reactive with peptides, no. 1 to 4 covering amino acids 1 to 50 and with peptide no. 5 covering amino acids 41 to 60. Only one of the sera from CIN patients was reactive with peptides no. 1 (amino acids 1 to 20) and no. 4 (amino acids 31 to 50). However, the majority of these sera reacted with peptide no. 5. The occurrence of this antibody was only slightly less frequent in sera from healthy subjects compared to CIN patients. On the other hand, sera from the INCA patients were reactive with the peptides no. 1 to 3 more frequently than the sera from matched control subjects. Positive reactions of sera from INCA patients were most frequently seen with no. 2; 24% of these sera but only 7% of the controls were reactive with no. 2 peptide. The present data suggest that no. 1 to 3 are HPV-16-specific, whereas no. 5 is broadly cross-reactive.
引用
收藏
页码:2719 / 2724
页数:6
相关论文
共 17 条
[1]   PRESENCE AND TYPE SPECIFICITY OF PAPILLOMAVIRUS ANTIBODIES DEMONSTRABLE BY IMMUNOELECTRON MICROSCOPY TESTS IN SAMPLES FROM PATIENTS WITH WARTS [J].
ANISIMOVA, E ;
BARTAK, P ;
VLCEK, D ;
HIRSCH, I ;
BRICHACEK, B ;
VONKA, V .
JOURNAL OF GENERAL VIROLOGY, 1990, 71 :419-422
[2]   ASSOCIATION OF SOME SUPRAGLOTTIC LARYNGEAL CARCINOMAS WITH EB VIRUS [J].
BRICHACEK, B ;
HIRSCH, I ;
SIBL, O ;
VILIKUSOVA, E ;
VONKA, V .
INTERNATIONAL JOURNAL OF CANCER, 1983, 32 (02) :193-197
[3]   A SYNTHETIC PEPTIDE DEFINES A SEROLOGIC IGA RESPONSE TO A HUMAN PAPILLOMAVIRUS-ENCODED NUCLEAR ANTIGEN EXPRESSED IN VIRUS-CARRYING CERVICAL NEOPLASIA [J].
DILLNER, J ;
DILLNER, L ;
ROBB, J ;
WILLEMS, J ;
JONES, I ;
LANCASTER, W ;
SMITH, R ;
LERNER, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (10) :3838-3841
[4]   NUCLEOTIDE-SEQUENCE OF HUMAN PAPILLOMAVIRUS TYPE-31 - A CERVICAL NEOPLASIA-ASSOCIATED VIRUS [J].
GOLDSBOROUGH, MD ;
DISILVESTRE, D ;
TEMPLE, GF ;
LORINCZ, AT .
VIROLOGY, 1989, 171 (01) :306-311
[5]   ANTIBODIES AGAINST THE HUMAN PAPILLOMAVIRUS TYPE-16 EARLY PROTEINS IN HUMAN-SERA - CORRELATION OF ANTI-E7 REACTIVITY WITH CERVICAL-CANCER [J].
JOCHMUSKUDIELKA, I ;
SCHNEIDER, A ;
BRAUN, R ;
KIMMIG, R ;
KOLDOVSKY, U ;
SCHNEWEIS, KE ;
SEEDORF, K ;
GISSMANN, L .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (22) :1698-1704
[6]  
KRCHNAK V, 1989, METHOD ENZYMOL, V178, P586
[7]   CONTINUOUS-FLOW SOLID-PHASE PEPTIDE-SYNTHESIS [J].
KRCHNAK, V ;
VAGNER, J ;
FLEGEL, M ;
MACH, D .
TETRAHEDRON LETTERS, 1987, 28 (38) :4469-4472
[8]   AMINO-ACIDS AND PEPTIDES .206. NONINVASIVE CONTINUOUS MONITORING OF SOLID-PHASE PEPTIDE-SYNTHESIS BY ACID-BASE INDICATOR [J].
KRCHNAK, V ;
VAGNER, J ;
SAFAR, P ;
LEBL, M .
COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, 1988, 53 (11A) :2542-2548
[9]  
KRCHNAK V, 1989, INT J PEPT PROT RES, V33, P209
[10]   THE HUMAN PAPILLOMAVIRUS TYPE-16 E7 GENE ENCODES TRANSACTIVATION AND TRANSFORMATION FUNCTIONS SIMILAR TO THOSE OF ADENOVIRUS-E1A [J].
PHELPS, WC ;
YEE, CL ;
MUNGER, K ;
HOWLEY, PM .
CELL, 1988, 53 (04) :539-547